Full-Time
Posted on 9/24/2025
Develops, produces, and markets diagnostic tests
$80k - $90k/yr
No H1B Sponsorship
Rochester, NY, USA
In Person
| , |
QuidelOrtho provides in vitro diagnostics (IVD) products, including diagnostic tests and equipment that use immunoassay and molecular testing to detect medical conditions. Its products are used in point-of-care settings, clinical laboratories, and transfusion medicine, serving individual healthcare providers to large institutions. The company develops and manufactures these tests and devices, which run on specialized platforms or point-of-care instruments to analyze patient samples and deliver quick, accurate results. What sets QuidelOrtho apart is its long history and the combination of Quidel’s and Ortho’s expertise into a broad portfolio, with a global reach and long-term contracts with healthcare providers. The company’s goal is to improve diagnostic accuracy and efficiency to support better patient outcomes and broad access to essential diagnostic solutions.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1937
Help us improve and share your feedback! Did you find this helpful?
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Employee Stock Purchase Plan
Paid Vacation
Paid Sick Leave
Paid Holidays
Employee Assistance Program
Wellness Program
QuidelOrtho Corporation has appointed Nathaniel Sisitsky as Chief Legal Officer, effective 23 March 2026. He will lead the diagnostic company's global legal, compliance and corporate governance functions, reporting to president and CEO Brian Blaser. Sisitsky brings over 25 years of legal experience in life sciences and technology sectors. He most recently served as Chief Legal Officer and Corporate Secretary at STAAR Surgical Company. Previously, he held senior legal roles at NuVasive, CareFusion Corporation and American Tower Corporation. He succeeds Michelle Hodges, who is retiring after years with QuidelOrtho. Hodges will serve in an advisory role to ensure a smooth transition. Sisitsky holds a Juris Doctor from New York University School of Law.
Nathaniel Sisitsky joins QuidelOrtho as Chief Legal Officer. Provided by PR Newswire Mar 24, 2026, 4:00:00 AM Nathaniel Sisitsky joins QuidelOrtho as Chief Legal Officer PR Newswire SAN DIEGO, March 24, 2026. SAN DIEGO, March 24, 2026 /PRNewswire/ - QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global leader of in vitro diagnostics, is pleased to announce the appointment of Nathaniel "Nate" Sisitsky as its new Chief Legal Officer, effective March 23, 2026. He will report to Brian Blaser, President and Chief Executive Officer, and will lead QuidelOrtho's global legal, compliance and corporate governance functions. Mr. Sisitsky brings more than 25 years of legal and governance experience advising public companies across life sciences and technology sectors. Most recently, he served as Chief Legal Officer and Corporate Secretary at STAAR Surgical Company, where he oversaw global legal and compliance functions. "Nate is a seasoned legal executive with deep experience navigating complex public company environments," said Brian Blaser, President and Chief Executive Officer, QuidelOrtho. "He brings a thoughtful, business-oriented approach to legal leadership and a strong track record of guiding organizations through transformations, governance matters and global regulatory matters. We are pleased to welcome him to QuidelOrtho as we continue advancing our strategy and strengthening our foundation for long-term growth." Mr. Sisitsky succeeds Michelle Hodges, who is retiring after a distinguished career and years of service to QuidelOrtho. Ms. Hodges played an important role in strengthening the Company's legal and governance capabilities, supporting strategic initiatives and guiding the organization through a period of significant transformation. Ms. Hodges will serve in an advisory role to facilitate a smooth transition. Throughout his career, Mr. Sisitsky has provided legal leadership during periods of significant organizational change across the medtech sector. His roles as Senior Vice President, General Counsel and Corporate Secretary at NuVasive, Inc. and CareFusion Corporation included guiding legal and compliance functions through major corporate transitions, ensuring continuity and strategic alignment across global operations. "I'm excited to join QuidelOrtho and contribute to a company that plays such a vital role in global healthcare," said Mr. Sisitsky. "Diagnostics are essential to informed medical decision-making, and QuidelOrtho has an important opportunity to continue advancing innovation that improves patient care worldwide. I look forward to working alongside Brian and the leadership team to support the Company's mission and long-term growth." Mr. Sisitsky began his legal career at Wilmer Cutler Pickering Hale and Dorr LLP. He later served in senior legal roles at American Tower Corporation before moving into leadership positions across the medical technology sector. He holds a Juris Doctor from New York University School of Law and a Bachelor of Arts in Political Science and Economics from Emory University. QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X. About QuidelOrtho Corporation With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, dedicated to advancing fast, accurate and reliable results that help improve patient outcomes - from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care. Investor Contact: Juliet Cunningham Vice President, Investor Relations [email protected] Media Contact: D. Nikki Wheeler Senior Director, Corporate Communications [email protected] View original content to download multimedia:https://www.prnewswire.com/news-releases/nathaniel-sisitsky-joins-quidelortho-as-chief-legal-officer-302722706.html SOURCE QuidelOrtho Corporation The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar. Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees. Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Rice Hall James Associates disclosed the purchase of 574,877 shares of QuidelOrtho (NASDAQ:QDEL) during the fourth quarter, according to a 13 February SEC filing. The additional shares increased the fund's position value by $16.2 million and brought its QuidelOrtho stake to 1.3% of assets under management. QuidelOrtho, a global diagnostics company, develops and manufactures diagnostic testing technologies across laboratories, transfusion medicine and molecular diagnostics. The stock traded at $23.58 on 13 February, down 43.4% over the past year. The company has faced challenges with revenue growth and profitability but made strategic leadership changes last year. Analysts expect modest growth in adjusted revenue and operating profit as the company strengthens its product pipeline and focuses on improving returns.
QuidelOrtho shares have fallen 19.9% over the past six months, underperforming the S&P 500's 6.6% gain, as the company currently trades at $22.11. The medical devices and diagnostics company has shown concerning trends across key metrics. Its constant currency revenue has declined by an average of 3.8% year-on-year over the past two years, suggesting increasing competition or market saturation. The company's free cash flow margin has dropped 21.9 percentage points over five years and now stands at negative 3% for the trailing 12 months. Additionally, QuidelOrtho's return on invested capital has decreased significantly, indicating fewer profitable growth opportunities. Despite trading at 10.5× forward P/E following the recent decline, analysts suggest investors look elsewhere for better opportunities.
Strategic supply agreement for QuidelOrtho. * February 16, 2026 QuidelOrtho has entered a long-term strategic supply agreement with Chinese firm Lifotronic Technology, to expand its global immunoassay portfolio and accelerate customer access to scalable, high quality, cost-efficient solutions across select markets outside the United States. The agreement provides QuidelOrtho access to multiple high-throughput and low-to-mid volume immunoassay analyser platforms, each supported by a broad menu of assays spanning routine and specialty testing. The collaboration is expected to expand QuidelOrtho's immunoassay menu with more than 25 new assays on these systems that are not currently available on the VITROS system, within a total menu of over 70 assays on these new partner platforms. These additions are planned to increase QuidelOrtho's ability to compete for full-menu tenders and serve a wider range of laboratory settings, from smaller laboratories seeking low-volume solutions to larger, high-throughput environments that require scalable capacity and broad test menus. Bryan Hanson, Senior Vice President of Global Clinical Laboratory and Transfusion Medicine at QuidelOrtho, said: "Through our collaboration with Lifotronic Technology, QuidelOrtho will rapidly introduce scalable testing solutions that further advance our long-term innovation strategy in core growth markets. This agreement strengthens our portfolio in markets where assay breadth and cost efficiency are key requirements, while offering customers a broader and more diverse set of solutions." Mr. Liu Xiancheng, Chairman of Lifotronic Technology, added: "This strategic partnership with QuidelOrtho marks an important milestone in Lifotronic Technology's global expansion strategy. Going forward, we will work closely with QuidelOrtho, continuing to leverage our in-house R&D strengths to deliver high-value diagnostic solutions that meet real clinical needs for customers worldwide." The commercial focus will be on Europe, the Middle East, Africa, Mexico, Central America, South America, India, China, Japan, and Asia-Pacific regions. This strategic expansion is planned to support QuidelOrtho's ability to address menu gaps, increase competitiveness in international tenders, and deliver more complete immunoassay solutions to laboratories seeking broader menus and flexible system options.